ORLY
54
-3
DHI
43
-2
BAX
38
3
ADP
61
-3
NI
58
-5
MAT
60
-5
AMAT
43
2
CMS
54
-4
FOXA
53
8
BAC
42
-2
DIS
50
-2
ITW
61
2
NKE
30
2
MMM
30
-3
CI
52
7
KMI
65
-4
ALL
35
-3
SEE
49
3
TGNA
35
-2
AME
54
-8
ORLY
54
-3
DHI
43
-2
BAX
38
3
ADP
61
-3
NI
58
-5
MAT
60
-5
AMAT
43
2
CMS
54
-4
FOXA
53
8
BAC
42
-2
DIS
50
-2
ITW
61
2
NKE
30
2
MMM
30
-3
CI
52
7
KMI
65
-4
ALL
35
-3
SEE
49
3
TGNA
35
-2
AME
54
-8
Financhill
Back

Verve Therapeutics 10K Form

Sell
1

VERV
Verve Therapeutics

Last Price:
6.04
Seasonality Move:
-35.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive VERV News And Ratings

See the #1 stock for the next 7 days that we like better than VERV

VERV Financial Statistics

Sales & Book Value

Annual Sales: $11.76M
Cash Flow: $-35.14M
Price / Cash Flow: 0
Annual Sales: $6.46
Price / Book: 0.92

Profitability

EPS (TTM): -2.59000
Net Income (TTM): $-192.65M
Gross Margin: --
Return on Equity: -36.29%
Return on Assets: -28.44%

Verve Therapeutics Earnings Forecast

Key Verve Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,572.94% of Revenue.
  • The Net Earning history of VERV is -1,701.55% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Verve Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: VERV
Website: vervetx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 14.64
Quick Ratio: 14.34

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

VERV Technical Analysis vs Fundamental Analysis

Sell
1
Verve Therapeutics (VERV) is a Sell

Is Verve Therapeutics a Buy or a Sell?